Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells

Area of Science:

• Immunology
• Cancer Biology
• Cellular Therapy

Background:

• Myeloid leukemic cells can differentiate into leukemia-derived dendritic cells (DCleu).
• DCleu present leukemic antigens and possess stimulatory capacity, but induced anti-leukemic T-cell responses vary in efficacy and specificity.
• Characterizing T-cell responses to DCleu is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

• To characterize the T-cell response pattern induced by leukemia-derived dendritic cells (DCleu) compared to leukemic blasts.
• To evaluate the T-cell stimulatory capacity, T-cell subset preference, and T-cell receptor (TCR) restriction patterns induced by DCleu.
• To explore the potential of DCleu-induced T-cell responses for therapeutic applications.

Main Methods:

• Immunoscope spectratyping to analyze T-cell receptor (TCR) rearrangements.
• Functional flow cytometry and non-radioactive fluorolysis assays to assess T-cell activity.
• Stimulation of human leucocyte antigen (HLA)-matched donor T-cells with leukemic blasts (FAB M4eo) and their derived DCleu.

Main Results:

• DCleu and leukemic blasts showed similar T-cell stimulatory capacity.
• DCleu favored T-cells with higher lytic activity and a greater proportion of T-memory CD45R0+ cells.
• DCleu stimulation induced a similar TCR restriction pattern to blasts but favored the CD4 T-cell subset with a higher grade of restriction.

Conclusions:

• A combined approach of spectratyping and functional tests can provide insights into T-cell response specificity and efficacy.
• DCleu demonstrate potential in enhancing anti-leukemic T-cell responses, particularly in the CD4+ T-cell subset.
• This strategy may facilitate the identification of effective T-cell clones for adoptive immunotherapy against leukemia.